– USA, CA – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company today announced the appointment of Caren Deardorf to its board of directors, bringing a broad experience in biotechnology, building on over 20 years at Biogen where she led commercial efforts for neurological diseases, including rare congenital disorders.
About Caren Deardorf
Caren Deardorf is currently CCO of Magenta Therapeutics, Inc., where she is responsible for the strategy, direction, and execution of Magenta’s global commercial capabilities. Earlier in her career, Ms. Deardorf was CCO of Ohana Biosciences and VP of global product development at Biogen, where she was the global commercial lead on Spinraza®, a treatment for children and adults with spinal muscular atrophy, or SMA, a genetic disease affecting muscle strength and movement. At Biogen, she led disease awareness efforts for the first drug approved to treat SMA, a rare and often fatal inherited disease that typically presents in infancy. Earlier in her career at Biogen, Ms. Deardorf was responsible for brand and launch strategy for Tecfidera, a treatment for relapsing forms of multiple sclerosis. Ms. Deardorf earned a Bachelor of Science degree in biology at Tufts University and a Master of Business Administration from Olin Graduate School of Business at Babson College.
Ms. Deardorf, said, “Crinetics’ commitment to patients with rare endocrine disorders and neuroendocrine tumors was very compelling to me. I’m looking forward to working with the team, as they advance their promising pipeline programs through clinical development and prepare commercial strategies for paltusotine.”
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, paltusotine, is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United States. A Phase 3 clinical program in acromegaly with paltusotine is underway. Crinetics also plans to advance paltusotine into a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors. The company is also developing CRN04777, an investigational, oral, nonpeptide somatostatin receptor type 5 agonist for congenital hyperinsulinism, as well as CRN04894, an investigational, oral, nonpeptide ACTH antagonist for the treatment of congenital adrenal hyperplasia, Cushing’s disease, and other diseases of excess ACTH. All of the company’s drug candidates are new chemical entities resulting from in-house drug discovery efforts.
For more information: https://crinetics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
